MoonLake Immunotherapeutics
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
MLTX$12.56-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, and
CONSOLIDATED BALANCE SHEETS
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $180,426,449 | $451,169,337 |
| Short-term marketable debt securities | 267,600,900 | 59,838,900 |
| Other receivables | 2,843,198 | 1,056,862 |
| Prepaid expenses - current | 23,418,298 | 2,102,203 |
| Total current assets | 474,288,845 | 514,167,302 |
| Non-current assets | ||
| Operating lease right-of-use assets | 2,922,211 | 3,628,480 |
| Property and equipment, net | 722,226 | 320,865 |
| Prepaid expenses - non-current | — | 8,423,468 |
| Total non-current assets | 3,644,437 | 12,372,813 |
| Total assets | $477,933,282 | $526,540,115 |
| Current liabilities | ||
| Trade and other payables | $8,992,479 | $1,837,684 |
| Short-term portion of operating lease liabilities | 1,371,962 | 1,197,876 |
| Accrued expenses and other current liabilities | 12,099,420 | 6,930,120 |
| Total current liabilities | 22,463,861 | 9,965,680 |
| Non-current liabilities | ||
| Long-term portion of operating lease liabilities | 1,457,598 | 2,499,990 |
| Pension liability | 620,684 | 583,426 |
| Total non-current liabilities | 2,078,282 | 3,083,416 |
| Total liabilities | 24,542,143 | 13,049,096 |
| Commitments and contingencies (Note 16) | ||
| Equity | ||
| Class A Ordinary Shares: $0.0001 par value; 500,000,000 shares authorized; 63,077,431 shares issued and outstanding as of December 31, 2024, 60,466,453 shares issued and outstanding as of December 31, 2023 | 6,308 | 6,047 |
| Class C Ordinary Shares: $0.0001 par value; 100,000,000 shares authorized; 841,269 shares issued and outstanding as of December 31, 2024, 2,505,476 shares issued and outstanding as of December 31, 2023 | 84 | 251 |
| Additional paid-in capital | 677,414,830 | 609,969,236 |
| Accumulated deficit | (235,592,989) | (116,657,472) |
| Accumulated other comprehensive income | 4,996,769 | 2,357,621 |
| Total shareholders’ equity | 446,825,002 | 495,675,683 |
| Noncontrolling interests | 6,566,137 | 17,815,336 |
| Total equity | 453,391,139 | 513,491,019 |
| Total liabilities and equity | $477,933,282 | $526,540,115 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.